EUVIMEDOpdag EUVIMED
ValidierungsstudieKohortenstudieOpen access · CC BY-NC 4.0

Development and Validation of an XGBoost ‐ SHAP Model for Predicting Adverse Outcomes in Elderly Cardiovascular Patients With Polypharmacy: A Retrospective Cohort Study

Kun Wang, Dandan Cao iD

Pharmacology Research & Perspectives · 2026-08 · 14 (4)

DOI: 10.1002/prp2.70293 ↗

At a glance

Validierungsstudie in Pharmacology Research & Perspectives, published online on 2026-07-01. Written by Kun Wang and 1 co-authors. Institution: Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, China. Major MEDLINE topics: Polypharmacy, Cardiovascular Diseases, Drug-Related Side Effects and Adverse Reactions. 52 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

This study aims to develop and validate an interpretable machine learning model using Extreme Gradient Boosting (XGBoost) with SHapley Additive exPlanations (SHAP) analysis to predict adverse outcomes in elderly cardiovascular patients with polypharmacy. This retrospective cohort study included 1200 patients aged ≥ 65 years with cardiovascular disease and polypharmacy (≥ 5 medications) from The First Affiliated Hospital of Soochow University between January 2021 and December 2024. Data were split into training (60%), validation (20%), and test (20%) sets. The primary outcome was adverse drug events (ADEs); secondary outcomes included 30‐day readmission, 90‐day readmission, and 1‐year mortality. XGBoost models were developed and compared with logistic regression, random forest, and support vector machine algorithms. Model interpretability was enhanced using SHAP values to identify key predictive features and their contributions. The cohort had a mean age of 76.34 ± 8.12 years, with 18.92% experiencing ADEs during follow‐up. The XGBoost model demonstrated strong discriminative ability for ADE prediction (AUC 0.857, 95% CI: 0.790–0.910) compared to logistic regression (AUC 0.795, p < 0.001). The model also performed well for secondary outcomes: 30‐day readmission (AUC 0.843, 95% CI: 0.779–0.899), 90‐day readmission (AUC 0.848, 95% CI: 0.784–0.895), and 1‐year mortality (AUC 0.873, 95% CI: 0.807–0.929), all significantly superior to logistic regression (all p < 0.001). At optimal thresholds, the model achieved sensitivity ranging from 62.71% to 90.24% and specificity from 67.84% to 87.85% across outcomes. SHAP analysis identified age (importance: 0.196), estimated glomerular filtration rate (0.181), medication count (0.159), serum albumin (0.147), and Charlson Comorbidity Index (0.138) as the most influential predictors. The model maintained good calibration (Brier scores: 0.156–0.164) and consistent performance across patient subgroups. SHAP threshold analysis identified eGFR < 45 mL/min/1.73 m 2 and serum albumin < 3.5 g/dL as key risk boundaries associated with markedly elevated adverse drug event risk. The XGBoost‐SHAP model provides accurate, interpretable prediction of adverse outcomes in elderly cardiovascular patients with polypharmacy. This approach may facilitate personalized risk assessment and targeted interventions to improve medication safety in this vulnerable population.

Subjects

MeSH terms (MEDLINE)

PolypharmacyCardiovascular DiseasesDrug-Related Side Effects and Adverse ReactionsHumansBoosting Machine Learning AlgorithmsRetrospective StudiesFemaleAgedPredictive Learning ModelsMaleAged, 80 and overLogistic ModelsPatient ReadmissionPrediction AlgorithmsRandom ForestSupport Vector Machine

Author keywords

SHAPXGBoostadverse drug eventscardiovascular diseaseelderlyinterpretable artificial intelligencemachine learningpolypharmacyrisk prediction

Authors and institutions

  • Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, China.

ORCID profiles: Dandan Cao

Cite

APA

Wang, K., & Cao, D. (2026). Development and Validation of an XGBoost ‐ SHAP Model for Predicting Adverse Outcomes in Elderly Cardiovascular Patients With Polypharmacy: A Retrospective Cohort Study. Pharmacology Research & Perspectives, 14(4). https://doi.org/10.1002/prp2.70293

Vancouver

Wang K, Cao D. Development and Validation of an XGBoost ‐ SHAP Model for Predicting Adverse Outcomes in Elderly Cardiovascular Patients With Polypharmacy: A Retrospective Cohort Study. Pharmacology Research & Perspectives. 2026;14(4). doi:10.1002/prp2.70293

BibTeX
@article{Wang2026,
  author = {Wang, Kun and Cao, Dandan},
  title = {Development and Validation of an XGBoost ‐ SHAP Model for Predicting Adverse Outcomes in Elderly Cardiovascular Patients With Polypharmacy: A Retrospective Cohort Study},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  volume = {14},
  number = {4},
  doi = {10.1002/prp2.70293}
}
Start for free →